Pharmaceutical

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast…

1 year ago

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and…

1 year ago

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal…

1 year ago

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment…

1 year ago

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

1 year ago

Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025 -First field tests of stacked…

1 year ago

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

1 year ago

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase I trialsSAN DIEGO and…

1 year ago